GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theranexus SA (XPAR:ALTHX) » Definitions » Capital Expenditure

Theranexus (XPAR:ALTHX) Capital Expenditure : €-0.04 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Theranexus Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Theranexus's cash flow for capital expenditures for the six months ended in Dec. 2023 was €-0.02 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.04 Mil.

Theranexus Capital Expenditure Historical Data

The historical data trend for Theranexus's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theranexus Capital Expenditure Chart

Theranexus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only -2.11 -0.25 -0.15 -0.07 -0.04

Theranexus Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.05 -0.02 -0.03 -0.02

Theranexus Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theranexus (XPAR:ALTHX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theranexus SA (XPAR:ALTHX) » Definitions » Capital Expenditure
Comparable Companies
XPAR:ALNFL XPAR:ALHYG XPAR:ALPAT XPAR:FALG XPAR:ALINT XPAR:ALVET XPAR:POXEL XPAR:ALBPS XPAR:ALMDP XPAR:ALQGC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
3VG:Germany
Address
60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008
Website
https://www.theranexus.com
Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.

Theranexus (XPAR:ALTHX) Headlines

No Headlines